Severity of MI compared between sDMARD and TNFi cohorts
| Number of verified first MIs with additional MINAP data | Group 1 (sDMARD), n=35 | Group 2 (on TNFi at the time of or within 90 days prior to MI), n=108 | Group 3 (exposure to TNFi more than 90 days prior to MI), n=55 | p Value |
|---|---|---|---|---|
| Proportion of patients with STEMI, n (%) | 16 (46) | 53 (49) | 27 (49) | 0.32 |
| Cardiac arrest, n (%) | 3 (9) | 5 (5) | 5 (9) | 0.48 |
| Median peak CK, IU/L (IQR) | 290 (172, 1598) | 691 (150, 1293) | 286 (125, 660) | 0.19 |
| Median peak troponin I, μg/L (IQR) | 5.0 (1.3, 7.2) | 7.4 (1.1, 22.8) | 7.6 (1.5, 29.0) | 0.46 |
| Median peak troponin T, μg/L (IQR) | 0.7 (0.3, 2.3) | 0.9 (0.2, 2.3) | 0.8 (0.2, 2.1) | 0.95 |
| Median length of hospital stay, days (IQR) | 6 (5, 9) | 6 (4, 8) | 6 (4, 11) | 0.46 |
CK, creatine kinase; MI, myocardial infarction; MINAP, Myocardial Ischaemia National Audit Project; sDMARD, synthetic disease modifying anti-rheumatic drug; STEMI, ST-elevation myocardial infarction; TNFi, tumour necrosis factor α inhibitor.